Deepu Madduri

Search results

• Data on Multiple Myeloma Described by Researchers at Mount Sinai Medical Center (Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/refractory Multiple Myeloma In ...)

  Deepu Madduri & Sundar Jagannath

  6/02/23

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System: Potentially Serious Side Effect Seen in Patient after Immunotherapy

  Samir Parekh, Miriam Merad, Seunghee Kim-Schulze, Joshua Brody, Adeeb Rahman, Sundar Jagannath, Alessandro Laganà, Charles Stacy, Julie Teruya-Feldstein & Deepu Madduri

  10/12/21 → 11/12/21

  8 items of Media coverage

  Press/Media

• Scientists identify new types of a blood cancer and potential targeted treatments

  David Melnekoff, Joshua Richter, Samir Parekh, Violetta V. Leshchenko, Ajai Chari, Sundar Jagannath, Alessandro Laganà, Joel Dudley, Kenen Onel, Deepu Madduri & Hearn Cho

  17/11/21

  1 item of Media coverage

  Press/Media

• Cilta-Cel Induces Deep and Durable Responses in Patients with Multiple Myeloma

  Deepu Madduri

  29/07/21

  1 item of Media coverage

  Press/Media

• Many Factors Influence Which Cell-Based Treatment Options are Best for Patients with Multiple Myeloma, Expert SaysArticle

  Deepu Madduri

  30/03/21

  1 item of Media coverage

  Press/Media

• CAR T-CELL THERAPY GENERATES LASTING REMISSIONS IN PATIENTS WITH MULTIPLE MYELOMA

  Deepu Madduri

  24/02/21 → 25/02/21

  3 items of Media coverage

  Press/Media

• CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

  Deepu Madduri

  24/02/21

  4 items of Media coverage

  Press/Media

• CART T Elicits Strong Response for Multiple Myeloma

  Deepu Madduri

  8/02/21

  1 item of Media coverage

  Press/Media

• Harnessing the Potential of Cell and Gene Therapy

  Deepu Madduri

  4/02/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year

  Deepu Madduri

  22/01/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma

  Deepu Madduri

  20/01/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial

  Deepu Madduri

  18/01/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results

  Deepu Madduri

  14/01/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

  Deepu Madduri

  13/01/21

  1 item of Media coverage

  Press/Media

• Deepu Madduri, MD, on the Results of the Phase 1b/2 CARTITUDE-1 Trial

  Deepu Madduri

  11/01/21

  1 item of Media coverage

  Press/Media

• CAR-T a ‘fantastic improvement’ over available therapies for advanced multiple myeloma

  Deepu Madduri

  11/01/21

  1 item of Media coverage

  Press/Media

• JOHNSON & JOHNSON : Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myel

  Deepu Madduri

  24/12/20

  1 item of Media coverage

  Press/Media

• BCMA/CD3-Targeted Drug Yields High Response Rates in R/R Myeloma

  Deepu Madduri

  22/12/20

  1 item of Media coverage

  Press/Media

• FDA Pushes Pause on 2 Regeneron Lymphoma Trials for Cytokine Release Syndrome

  Deepu Madduri

  15/12/20

  1 item of Media coverage

  Press/Media

• Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

  Deepu Madduri

  14/12/20

  1 item of Media coverage

  Press/Media

• Myeloma: CAR T-Cell Therapy Produces Deep and Durable Responses

  Deepu Madduri

  14/12/20

  1 item of Media coverage

  Press/Media

• United States : Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

  Deepu Madduri

  10/12/20

  1 item of Media coverage

  Press/Media

• Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma

  Deepu Madduri

  9/12/20

  2 items of Media coverage

  Press/Media

• United States : Regeneron's Bcmaxcd3 Bispecific Antibody (Regn5458) Shows Deep And Durable Responses In Patients With Heavily-pretreated Multiple Myeloma In Phase 1

  Deepu Madduri

  9/12/20

  1 item of Media coverage

  Press/Media

• Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

  Deepu Madduri

  8/12/20

  1 item of Media coverage

  Press/Media